证券代码：002275 证券简称：桂林三金 公告编号：2024-032 二、监事会会议审议情况 1.审议通过了《2024年第三季度报告》（同意票3票，反对票0票，弃权票0 票）。 【详细内容见2024年10月30日《中国证券报》《证券时报》《证券日报》及 巨潮资讯网（http://www.cninfo.com.cn）发布的公司《2024年第三季度报告》】 桂林三金药业股份有限公司 第八届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 桂林三金药业股份有限公司（以下简称"公司"）于2024年10月18日以书面 和电子邮件方式向监事发出第八届监事会第八次会议通知，会议于2024年10月29 日在广西壮族自治区桂林市临桂区人民南路9号公司会议室举行。本次会议应出 席会议的监事3人，实际出席会议的监事3人，会议由监事会主席阳忠阳先生主持， 会议召开程序符合《公司法》及《公司章程》的有关规定。 公司第八届监事会第八次会议决议。 特此公告。 经审核，监事会认为：董事会编制和审议公司《2024年第三季度报告》的程 序符合法律 ...

桂林三金药业股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开 第八届董事会第九次会议及 2024 年 5 月 16 日召开 2023 年度股东大会审议通过 了《关于 2024 年度为孙公司提供担保额度预计的议案》，同意公司及控股子公司 为全资孙公司宝船生物医药科技（上海）有限公司（以下简称"宝船生物"）和 白帆生物科技（上海）有限公司（以下简称"白帆生物"）（资产负债率均超过 70%）新增提供总金额不超过人民币 2 亿元的担保（其中宝船生物不超过人民币 0.5 亿元，白帆生物不超过人民币 1.5 亿元），担保额度有效期自 2023 年度股东 大会审议通过之日起至 2024 年度股东大会召开之日，上述担保额度可循环使用， 担保方式包括但不限于连带责任担保、抵押担保等方式。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 具体内容详见公司于 2024 年 4 月 26 日在《中国证券报》《证券时报》《证券 日报》及巨潮资讯网（http://www.cninfo.com.cn）发布的公司《关于 2024 年 度为孙公司提供担保 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2024030 | --- | --- | --- | |-------------------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □ 现场参观 | ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2024031 | --- | --- | --- | |-------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

2、《从稳健到成长，从航母到舰队》2023-11-23 证券研究报告 | 公司动态点评 2024 年 09 月 01 日 桂林三金（002275.SZ） Q2 业绩超预期，核心产品需求有支撑 | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------|-------|--------------------------|-------|-------|-------|------------------------------------------|----------| | 财务指标 | 2022A | 2023A | 2024E | 2025E | 2026E | 买入（维持评级） | | | | | | | | | | | | 营业收入（百万元） | 1,960 | 2,172 | 2,356 | 2,545 | 2,774 | | | | 增长率 yoy （ % ） | 12.5 | 10.8 | 8.5 | 8.0 | 9.0 | 股票信息 | | | 归母净利润（百 ...

关于为孙公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 桂林三金药业股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开 第八届董事会第九次会议及 2024 年 5 月 16 日召开 2023 年度股东大会审议通过 了《关于 2024 年度为孙公司提供担保额度预计的议案》，同意公司及控股子公司 为全资孙公司宝船生物医药科技（上海）有限公司（以下简称"宝船生物"）和 白帆生物科技（上海）有限公司（以下简称"白帆生物"）（资产负债率均超过 70%）新增提供总金额不超过人民币 2 亿元的担保（其中宝船生物不超过人民币 0.5 亿元，白帆生物不超过人民币 1.5 亿元），担保额度有效期自 2023 年度股东 大会审议通过之日起至 2024 年度股东大会召开之日，上述担保额度可循环使用， 担保方式包括但不限于连带责任担保、抵押担保等方式。 具体内容详见公司于 2024 年 4 月 26 日在《中国证券报》《证券时报》《证券 日报》及巨潮资讯网（http://www.cninfo.com.cn）发布的公司《关于 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2024027 | --- | --- | --- | |-------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2024028 | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：002275 证券简称：桂林三金 公告编号：2024-025 桂林三金药业股份有限公司 关于公司实际控制人、董事长兼总裁增持股份计划实 施完成的公告 邹洵先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1.增持计划的基本情况：桂林三金药业股份有限公司（以下简称"公司"） 于2024年3月2日披露了《关于公司实际控制人、董事长兼总裁增持公司股份计划 的公告》（公告编号：2024-002），公司实际控制人、董事长兼总裁邹洵先生计划 使用自有资金自2024年3月2日起六个月内通过深圳证券交易所集中竞价或大宗 交易方式增持公司股份，增持金额不低于500万元人民币。 2.增持计划实施情况：2024年3月2日至2024年9月1日期间，邹洵先生通过深 圳证券交易所以集中竞价方式累计增持公司股份383,000股，占公司总股本的 0.07%，累计增持金额为人民币504.58万元。本次增持计划已实施完成 。 近日，公司收到邹洵先生出具的《关于股份增持计划实施完成的告知函》， 截至2024年9月1日，本 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 1,068,416,486.86, a decrease of 10.53% compared to CNY 1,194,164,221.75 in the same period last year[11]. - Net profit attributable to shareholders was CNY 300,972,383.95, down 20.70% from CNY 379,540,846.40 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was CNY 274,202,045.76, a decline of 25.21% compared to CNY 366,606,512.13 in the previous year[11]. - Basic earnings per share decreased by 21.54% to CNY 0.51 from CNY 0.65 year-on-year[11]. - The total profit for the same period was CNY 355.13 million, down 18.16% year-on-year[38]. - The company reported a net increase in cash and cash equivalents of ¥110,632,586.73, representing a 193.98% increase from ¥37,633,240.70 in the previous year[40]. - The company achieved a net profit of CNY 300 million, up 20% compared to the same period last year[77]. - The company reported a total revenue of 1.5 billion yuan for the first half of 2024, representing a year-over-year increase of 12%[79]. Cash Flow and Investments - The net cash flow from operating activities increased by 7.16% to CNY 203,323,264.12 from CNY 189,745,271.10 in the same period last year[11]. - Investment activities generated a net cash flow of ¥128,227,952.69, a significant increase of 1,880.55% from ¥6,474,371.52 year-on-year[40]. - Cash inflow from investment activities totaled CNY 584,225,131.07, a decrease from CNY 648,815,164.96 in the first half of 2023, representing a decline of about 9.9%[141]. - The company reported a total investment of approximately 330,000 yuan in environmental monitoring and maintenance of pollution control facilities in the first half of 2024[85]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,808,031,326.26, a decrease of 3.25% from CNY 3,936,044,324.47 at the end of the previous year[11]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,209,613,775, representing 31.76% of total assets, an increase of 4.88% from the previous year[44]. - Accounts receivable increased to ¥206,222,982, accounting for 5.42% of total assets, up by 3.41% due to annual credit granted to distributors[44]. - The total liabilities decreased from CNY 2,197,046,491.93 to CNY 2,136,339,883.03, reflecting a decrease of about 2.77%[129]. Research and Development - Research and development expenses increased by 23.49% to ¥79,034,405.40, up from ¥64,000,850.57 in the previous year[40]. - The company is investing 100 million yuan in R&D for new technologies aimed at improving production efficiency and reducing waste emissions[80]. - The company is focusing on expanding its product offerings in health and hygiene sectors, including medical masks and disinfectants[57]. Market Position and Strategy - The company aims to strengthen its market position in oral and urinary health, with a focus on developing products for common diseases across various systems[19]. - The company has established a leading position in the traditional Chinese medicine sector, ranking 29th in the 2023 Top 100 Chinese Medicine Enterprises and 56th in the Top 100 Traditional Chinese Medicine Industry Rankings[18]. - The company is positioned to benefit from increasing demand for traditional Chinese medicine due to rising health awareness and aging population trends in China[16]. - The company plans to enhance brand building and product competitiveness through innovation and cost reduction strategies to mitigate the risks associated with centralized procurement[60]. Environmental Compliance - The company has received a national pollution discharge permit valid until December 2026, reinforcing its commitment to environmental standards[79]. - The company achieved compliance with all environmental discharge standards, with no significant environmental issues or pollution incidents reported during the period[83]. - The company plans to decommission two gas boilers (4 tons of steam) and switch to centralized steam supply starting July 2024[83]. Risks and Challenges - The company faces risks such as industry policy changes, product price declines, and intensified market competition[2]. - The company plans to enhance risk management and adapt product structures in response to evolving national policies[59]. - The company’s first-line products, such as Xigua Frost and Sanjin Tablets, account for a high proportion of sales revenue, making it vulnerable to adverse changes in raw material prices and market competition[61]. Shareholder Information - The company has no plans for cash dividends or stock bonuses for the half-year period, focusing instead on maintaining financial stability[68]. - The employee stock ownership plan remains active with 233 participants holding a total of 6,147,976 shares, representing 1.05% of the company's total equity[69]. - The company distributed cash dividends of 176,270,580.00 yuan to shareholders, with a payout of 3.00 yuan per 10 shares[113].